<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68711">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766440</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06. SPR.18104</org_study_id>
    <nct_id>NCT01766440</nct_id>
  </id_info>
  <brief_title>PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the calcitriol absorption in pediatric subjects
      is comparable to that in adults and adolescents, with no significant impact on
      calcium/phosphorus metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>C max of calcitriol plasma level</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>C min of calcitriol plasma level</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>T max of calcitriol plasma level</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of calcitriol plasma level</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium homeostasis parameters</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum calcium, albumin-adjusted calcium, serum phosphorus, serum albumin, intact PTH and urinary calcium/creatinine ratio</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Calcitriol 3 mcg/g ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application every 12 hours for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol 3 mcg/g ointment</intervention_name>
    <arm_group_label>Calcitriol 3 mcg/g ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female pediatric subjects, 2 to 12 years of age inclusive at screening

          -  Clinical diagnosis of plaque type psoriasis involving 5% through 35% body surface
             area at screening and baseline (excluding face and scalp)

        Exclusion Criteria:

          -  Subjects with guttate or pustular psoriasis, erythrodermic psoriasis or active
             infection

          -  Subjects with hypercalcemia and out of range urinary calcium/creatinine ratio at
             screening

          -  Subjects with secondary hyperparathyroidism at screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Anderson</last_name>
    <phone>609-860-8236</phone>
    <email>sarah.anderson@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rady Children's Hospital - Pediatric and Adolescent Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Borok, RN,CCRC</last_name>
      <phone>858-576-1700</phone>
      <phone_ext>4295</phone_ext>
      <email>nborok@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Lawrence Eichenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ameriderm Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Wallace</last_name>
      <phone>317-621-7731</phone>
      <phone_ext>119</phone_ext>
      <email>awallace@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Scott A Fretzin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Keeley, CCRP</last_name>
      <phone>734-763-9187</phone>
      <email>ktkeeley@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Yolanda Helfrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Dermatology and Skin Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hanami</last_name>
      <phone>919-843-5126</phone>
    </contact>
    <investigator>
      <last_name>Aida Lugo-Somolinos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Vanderah, RN, BSN</last_name>
      <phone>513-803-0003</phone>
    </contact>
    <investigator>
      <last_name>Kara Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TriCities Skin and Cancer</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Goins</last_name>
      <phone>423-989-3105</phone>
    </contact>
    <investigator>
      <last_name>Robert Clemons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia Robinson</last_name>
      <phone>972-354-7992</phone>
    </contact>
    <investigator>
      <last_name>Alan Menter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Oranday, LVN</last_name>
      <phone>210-949-0122</phone>
      <phone_ext>119</phone_ext>
    </contact>
    <investigator>
      <last_name>Elizabeth Tichy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janna Stults, MPH</last_name>
      <phone>206-884-3691</phone>
      <email>janna.stults@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Heather Brandling-Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
